Akero Therapeutics Inc. (AKRO)

Business: Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health.

IPO Date: 20-Jun-2019

Pres, CEO & Director: Dr. Andrew Cheng M.D., Ph.D.

Co-Founder, Exec. VP, COO & Sec.: Dr. Jonathan M. Young J.D., Ph.D.

Listing: NASDAQ: AKRO

Country: United States

Headquarters: South San Francisco, CA

Website: https://www.akerotx.com

Market cap: $359.34 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-111.72 Mln

Cash: $165.38 Mln

Total Debt: $1.47 Mln

Insider's Holding: 8.12%

Liquidity: Low

52 Week range: $7.52 - 26.98

Shares outstanding: 37,548,200

5 Years Aggregate:

• CFO: $-195.52 Mln
• EBITDA: $-240.41 Mln
• Net Profit: $-310.02 Mln